Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

KEY publications
IPC's Chief Medical Officer has selected the following publications as important to the understanding of the impact of COVID-19 and psoriasis. 

Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy. [published online ahead of print, 2020 May 26]. Brunasso AMG, Massone C.   2020;e13495. doi:10.1111/dth.13695.

 

Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemicLópez-Robles J, de la Hera I, Pardo J, Martínez J, Cutillas-Marco E. Clin Exp Dermatol. 2020 May 5. doi: 10.1111/ced.14275. [Epub ahead of print]


Performing dermoscopy in the COVID-19 pandemic. Goldust M, Zalaudek I, Gupta A, Lallas A, Rudnicka L, Navarini AA. Dermatol Ther. 2020 May 5:e13506. doi: 10.1111/dth.13506. [Epub ahead of print] 

View all

this weeks' publications on covid-19 & psoriasis

Icon for Elsevier Science Icon for PubMed Central Related Articles

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.

J Am Acad Dermatol. 2020 Sep 03;:

Authors: Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo RV, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT

Abstract
OBJECTIVE: To provide guidance about management of psoriatic disease during the COVID-19 pandemic.
STUDY DESIGN: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by non-voting members which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.
RESULTS: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus, 13 with moderate consensus.
LIMITATIONS: The evidence behind many guidance statements is limited in quality.
CONCLUSION: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.

PMID: 32891785 [PubMed - as supplied by publisher]

Icon for Wiley Related Articles

COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid.

Int J Dermatol. 2020 Sep 04;:

Authors: Fulgencio-Barbarin J, Puerta-Peña M, Ortiz-Romero P, García-Donoso C, Rivera-Diaz R

PMID: 32886364 [PubMed - as supplied by publisher]

Icon for PubMed Central Related Articles

Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey.

Patient Prefer Adherence. 2020;14:1403-1409

Authors: Wang Q, Luo Y, Lv C, Zheng X, Zhu W, Chen X, Shen M, Kuang Y

Abstract
Purpose: The COVID-19 epidemic has caused difficulties in continuous treatment for patients with chronic diseases and resulted in nonadherence to treatment and adverse health outcomes. This study aimed to investigate the associations of nonadherence to treatment with patient-reported outcomes of psoriasis during the COVID-2019 epidemic.
Methods: A cross-sectional study among Chinese patients with psoriasis was conducted through a web-based questionnaire survey during 25 Feb 2020 and 6 Mar 2020. Demographic and clinical data, nonadherence to treatment, and patient-reported outcomes were collected. The outcomes included deterioration of the disease condition, perceived stress, and symptoms of anxiety and depression. Logistic regression was used to investigate the associations.
Results: A total of 926 questionnaires were collected. A total of 634 (68.5%) reported nonadherence to treatment, and worse adherence was found among patients receiving systemic treatment (adjusted odds ratio [AOR]: 2.67; 95% CI: 1.40-5.10) and topical treatment (AOR: 4.51; 95% CI: 2.66-7.65) compared to biological treatment. Nonadherence to treatment (less than two weeks and more than two weeks) was significantly associated with deterioration of psoriasis (aOR: 2.83 to 5.25), perceived stress (AOR: 1.86 to 1.57), and symptoms of anxiety (AOR: 1.42 to 1.57) and depression (AORs: 1.78). Subgroup analysis by treatment showed consistent results in general.
Conclusion: Nonadherence to treatment was associated with the aggravation of psoriasis conditions, perceived stress, and symptoms of anxiety and depression.

PMID: 32884243 [PubMed]

VIEW ALL ON PUBMED

resources from our industry partners

 AbbVie
Amgen
Novartis
UCB

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK